Fulminant hepatitis A: Disappearing, but not soon enough

Hepatology

Volumn 44, Issue 6, 2006, Pages 1397-1399

  Koff, Raymond S ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; ERADICATION THERAPY; HEPATITIS A; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER FAILURE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; UNITED STATES; VACCINATION;

CHILD; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; INFANT; MALE; UNITED STATES;

EID: 33845612302     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21411     Document Type: Editorial

References (17)

1. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
2. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR07):1-23.
3. Kusov Y, Kanda T, Palmenberg A, Sgro JY, Gauss-Muller V. Silencing of hepatitis A virus infection by small interfering RNAs. J Virol 2006;80: 5599-5610.
4. Strom SC, Bruzzone P, Cai H, Ellis E, Lehmann T, Mitamura K, et al. Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant 2006;15(Suppl 1):S105-S110.
5. Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol 2006;35:109-112.
6. Sjogren M. Immunization and the decline of viral hepatitis as a cause of acute liver failure. HEPATOLOGY 2003;38:554-556.
7. Taylor R, Davern T, Munoz S, Han S-H, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. HEPATOLOGY 2006;44:1589-1597.
8. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-658.
9. Ellis AJ, Saleh M, Smith H, Portmann B, Gimson A, Williams R. Late-onset hepatic failure: clinical features, serology and outcome following transplantation. J Hepatol 1995;23:363-372.
10. Poison J, Lee WM. AASLD position paper: the management of acute liver failure. HEPATOLOGY 2005;41:1179-1197.
11. Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr 2005;40:575-581.
12. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005;12:101-105.
13. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290.
14. Sagnelli E, Coppola N, Pisaturo M, Pisapia R, Onofrio M, Sagnelli C, et al. Clinical and virologic improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Clin Infect Dis 2006;42:1536-1543.
15. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97:427-434.
16. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97:721-728.
17. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents and adults. HEPATOLOGY 2003;37:44-51.